Background This article provides an original method of estimating the prevalence of injecting drug users (IDU) in France.
Introduction
Determining the number of injecting drug users (IDU) in a population remains a public health challenge that goes beyond simple epidemiological observation: it constitutes an initial step in the process of estimating the economic burden of related diseases (HBV and HCV, 1,2 HIV 3 ), forecasting potential need for treatment, as well as being a key element in establishing and guiding prevention policies. 4, 5 Prevalence of IDU is also needed to help measure the dynamics of drug markets and provide a realistic basis upon which to measure the social cost of drug problems. However, research on IDU is hampered by the lack of information on their numbers. 6 The illicit nature of the related injected substances and the social disapproval of its use interfere with all attempts to directly count these users. 7 Traditional sampling methodologies, based on fragmentary information, prove unsatisfactory as illicit substance users and IDU inevitably evade general population surveys. Illicit and IDU tend to steer clear of specialized centres and consequently remain largely undetected by in-field institutions. 8 Thus, the treatment-seeking population provides an incomplete view of the overall number of substance users. In addition to the population actually observed (i.e. the population sampled or that appears in registers), there is a hidden population whose size must be estimated. As a result, indirect methods are favoured to provide more realistic figures.
Prior estimates of the number of illicit substance users in France at a national level were obtained mainly by multiplier methods or extrapolation of local figures. IDU were thought to be 81 000 (no confidence intervals provided) in 2006.
in the past decades. 7, 10 However, strong legal restrictions protecting the anonymity of illicit substance users in France hinder any attempt at data linkage. Moreover, this procedure has generally been met with great reluctance from within the medical community, labelling anonymity as an essential pre-condition in reaching as many users as possible. Thus the restriction to a single data source constitutes a plausible alternative attempt to obtain updated figures and prevalence. This study relies on an alternative dataset collected within treatment centres. Extrapolating data from treatment centres is a common procedure in estimating the prevalence of sub-groups of illicit substance users, by essence elusive. 11 Moreover, providing reliable estimates at national level remains a major challenge, an issue that is addressed in this paper. To extend the analysis, this study for the first time, also provides estimates of IDU in France broken down by gender and age groups.
Method Data
Each year, the French Monitoring Centre on Drugs and Drug Addictions (OFDT) produces an updated compendium on addictions and treatments (Recueil commun sur les addictions et les prises en charge-RECAP), carried out at national level. 12 Following the European protocol for registering treatment demands, one of the European Monitoring Centre on Drugs and Drug Addictions (EMCDDA)'s key indicators, all treatment centres are requested to provide data on clients welcomed into their premises during a full calendar year. Treatment centres in France are publicly funded, medically driven entities located within each of the sub-regional administrative areas. They provide free, anonymous access to all individuals seeking treatment for addictions, both to licit and/ or illicit substances, regardless of their incomes, professional status or age, and aim at a complete cessation of substance uses. Treatment centres provide outpatient (including in-prison) and inpatient services. Both medication-assisted treatments, such as methadone maintenance and buprenorphine prescription, and psychosocial treatment are provided. Until 2010, alcohol disorders and illicit substance misuses were treated separately, each in devoted premises. However, in 2011, the Social Security released a unified protocol stipulating that all treatment centres were to provide attention to substance users, regardless of the nature of the substance involved. Nowadays, treatment centres welcoming a majority of alcohol users but also a minority of illicit substance users are becoming more frequent. Due to its annual frequency, the number of inclusion in RECAP is fairly high (more than 169 000 clients in 2014), and provides sufficient statistical weight to analyse the characteristics of certain sub-groups of clients. The survey has gained approval of the National Data Protection Authority.
Questionnaire
The face-to-face, standardized questionnaire includes information on substance uses, health and sociodemographic characteristics. Here, treatment is perceived as a discontinuous, long-term process including seeking support, attending, relapses and engaging into a new treatment. Consequently, the number of treatment episodes recorded during a civil year is favoured over the number of contacts per se. Treatment centres are requested to provide information on the type of contact each individual establishes with the structure: first demand, uninterrupted treatment follow-up and readmission, defined as no contact with the referral centre for at least 6 months. 8, 13 This latter case is labelled as a new contact with the treatment centre, in which case individuals are assumed to be seen twice.
Case definition
The study focuses on all clients welcomed in treatment centres in 2014. The questionnaire includes a question on having used intravenous injection as a route of administration at least once in a lifetime, during the past year, during the past month. Any positive response to one of these questions classifies a client as an IDU.
Missing cases
Values to fill in missing responses in injecting drugs were imputed using Stata's MI (multiple imputation) procedure 14 as a function of age, gender, previous month uses of opioids (heroine, buprenorphine, methadone, morphine sulphates, other), stimulants (cocaine, crack, amphetamines, MDMA, others), hallucinogens (magic mushrooms, LSD), type of treatment centres and number of registrations during the calendar year. One recommendation in MI is that the imputation model should include the same variables that are in the analytic model, including the dependent variable, otherwise relationships with the variables that have been omitted will be biased toward 0. 15 
Statistical analysis
Estimates are based on a CR framework. 16, 17 CR methodology was first designed for estimating the size of animal populations, but has subsequently been extensively applied to human populations. CR consists in locating individuals in a sample or register (capture) and then checking if they appear in others (recapture). The estimated number of unobserved individuals is summed with those observed to form the total size of a given population. The use of CR techniques in epidemiology gained considerable popularity during the 1970s alongside the development of loglinear models, enabling the simultaneous use of three or more data sources. 7, 18 Several refinements have been introduced since the 1980s enabling the use of a single, less costly data source, including covariates and consequent estimates of sub-populations size. In the context of a CR framework using a single registration source, Zelterman 19 relies on zero-truncated Poisson distribution to estimate the size N est of a given population as N est ¼ N obs =ð1−p 0 Þ where the proportion of unobserved individuals isp 0 ¼ expð−2f 2 =f 1 Þ. Its calculation only requires the total of observed individuals N obs , the total of individuals appearing once (ƒ 1 ) and twice (ƒ 2 ), according to the empirical hypothesis that invisible individuals are more similar to individuals not seen often than to those seen often. 20, 21 Its widespread use in drug epidemiology is due to the simplicity in calculation and robustness, i.e. its resistance to the non-compliance with hypotheses limiting the CR method, particularly in the event of heterogeneity. [22] [23] [24] More sophisticated statistical inferences were suggested afterwards. [25] [26] [27] [28] More recently, Böhning and van der Heijden have generalized the Zelterman indicator to include covariates, yielding the Zelterman regression model. 23 They suggested the following formula to estimate the size of the population:
where I is an indicator of presence (I = 1 if individual i appears in the data and I = 0 otherwise) and λ the individual probability of appearing once or twice in the collected data, estimated by means of a logistic regression:
where y is the dependent variable (coded 0 if a client is recorded once, coded 1 if recorded twice), β 0 the constant, X the matrix of independent variables likely to influence the number of appearances (age, gender, reported substances, type of treatment centres, each variable tested one by one, retaining only variables that are statistically significant at P < 0.05), β their related coefficients and ε i a random error term, ε~N(0;σ 2 ε ). This method has been used to estimate the number of methamphetamine users in Bangkok, Thailand 23 and problem drug users in Amsterdam, the Netherlands. 24 While this method is useful in providing figures at a localized level, estimating at a wider geographical level remains a challenge so far unresolved. A supplementary step must be taken in order to achieve this goal: indeed, collecting information is based on the participation of individuals admitted to several centres, leading to a geographic and institutional clustering that must be controlled. Therefore, the model is written as follows:
where observations belong to a cluster j = 1, 2, 3…, J. The observations are indexed by I = 1, 2, 3…, M within each cluster, M is the number of observations per cluster and subsequently N = Σ j M = JM is the total number of observations. In practice, the β coefficients remain unchanged, but the standard errors associated with them are adjusted. In the context of a hierarchical data collection, multilevel modelling is a likely alternative. 6 Multilevel models are necessary to account for the hierarchical structure of the data with clients i nested in treatment centre j. Failure to take the average variance between centres into account will lead to biased results. In a two-level model, the probability that an individual appears more than once is estimated as follows:
where u .j is the error associated with centre j, u .j ∼N(0; σ 2 u.j ), and ε ij the error associated with individual i counted in centre j, of null mean and a variance of σ 2 . 29 Cluster-controlled logistic regressions and multilevel regressions are then compared by examining the Akaike 30 and Bayesian 31 information criterions to select the models that better fit the data. The method was previously applied to estimate the number of heroin users in metropolitan France. 32 The selection procedure follows several steps: first, a cluster controlled logistic regression is run and is compared to a two-level (individual and centres) model. Next, a three-level model is tested, accounting for individual, centres and regional level to better control a potential geographical heterogeneity in substance use, with mixed results however; the amount of variance measured with this additional level is very small, with loss in the measures of goodness of fit. The twolevel, more parsimonious model is therefore favoured. Then, models including substance uses as random effect are tested: in other words, variability in substance uses is not restricted to individual features but also refers to differences at centres level.
Results
The number of records, e.g. attendance at a treatment centre in 2014, broken down by gender are displayed in Table 1 .
Male IDU are overrepresented and more prone to be registered twice. As shown in Table 2 , the intraclass correlation shows values close or equal to 0.2 and the median OR greater than 2 in all cases, supporting the use of multilevel modelling. In all cases, the indexes of goodness of fit assert the superiority of multilevel modelling over the simple clustercontrolled logistic regression. Simple clustered logistic regression produce seriously downward biased estimates as shown in Table 3 . The lower values of information criterions suggest that a model with opioids and stimulants use as random-effect is the most appropriate for the data for last year and last month injection. The estimated coefficients used in the calculations of the updated estimates are shown in annex. Holding all other variables constant, female IDU are less likely to be registered twice as compared to male, as are younger IDU. Conversely, opioids users, known to be an ageing population, show a greater propensity to be registered more than once in treatment centres, as do hallucinogens users. Stimulant use is the only covariate showing no significant association with PWID being registered twice. Ceteris paribus, IDU observed in centres treating a majority of alcohol users are less likely to be registered more than once.
Accordingly, the estimated number of IDU during the last year was 103 800 (95% CI: 85 300; 130 000), prevalence of 2.55‰ of the 15-64 year old age group (2.10; 3.20) and during the last month, 86 000 (69 200; 110 400), prevalence of 2.12‰ (1.70; 2.72), respectively. Accounting for random effects is not a trivial issue: discarding those effects and opting for a random constant-only model yields overestimates of the number of last year IDU (+3300) and underestimates of (current) last month IDU (−3000). Estimates of the number of IDU broken down by gender are shown in Table 4 . Unsurprisingly, injecting drugs is a heavily gender-influenced practice, with a more than 3 to 1 ratio of male-to-female. Also, proportions of drug IDU in treatment (N obs /N est ) vary across gender, from 29% for female to 33% for male current IDU. The relative increase, illustrated by a lower sex ratio in last month injection (3.1, P < 0.001) as compared to last year injection (3.4, P < 0.001), suggests that injection has gained favour among females recently. In addition, the estimated numbers of IDU have been broken down by age groups. Reflecting the observed sample, the estimates suggest that IDU constitute a relatively young population, of which three-quarters are aged 44 or less. Last year and last month injection vary across age groups, reaching a peak among middle-aged adults.
Discussion
Main findings of the study
The male-to-female ratio accords with that observed in treatment centres across Europe, varying from 4 to 1 to 3 to 1.
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The study also suggests that one IDU out of three was registered in treatment centres in 2014. Low coverage illustrates the challenge for treatment centres in keeping up with a constantly changing, hard-to-reach population. If this coverage rate is somewhat superior to those estimated in prior studies, its rather modest level remains nonetheless a subject of public health concern. 34, 35 This issue is particularly sensitive regarding female IDU, who have been found to engage in more risk behaviours than males, 36 show faster transition to addiction, have a greater exposure to injection-related problems and are less likely to be granted access to treatment and harm reduction facilities. 37 For instance, females IDU in France were less likely to clean used needles 38, 39 and more prone to needle and syringe sharing than males, a trend that has been confirmed recently by outreach field studies. 40 Compared with middle-aged IDU, the proportion of 15-29 year olds last month IDU is smaller. Current injection among young adults is not as common as it is in older, more experienced drug users, and is certainly not their exclusive route of administration. This result is consistent with previous findings on IDU's trajectories, from onset at earlier ages followed by steady increase over time, with more frequent uses of intravenous injection at a later stage. 8, 13 What is already known on this topic
The number of last month IDU calculated in 2006 by means of a multiplier method was estimated to be 81 000, prevalence of 2.1‰ (no confidence intervals provided). 9 The prevalence of IDU has remained stable during the past decade, a trend confirmed by data collected among harm reduction facilities. 41 
What this study adds
There were thought to be 103 800 (85 300; 130 000) past year IDU in France, an estimate so far unreleased. Moreover, the study fills a crucial gap by providing estimates of IDU broken down by gender, and by age group, both important sources of information when estimating the prevalence of related diseases such as HVC and HIV. A comparison of the results against those of other European countries shows that France falls below the average prevalence of the European Union (2.5‰ of the 15-64 year olds 42 ) and those observed in other Western countries: past month/current injection of 3.9‰ (3.1; 4.7) in Canada 43 and 3.0‰ (2.0; 4.0) in the United States in 2011. 44 In Australia, the prevalence of IDU during the past month was estimated to be 5.0‰ in 2010 versus 8.0‰ in 2007. 45 The decreasing trend is thought to be related to the dramatic reduction in heroin supply during the 1990 and 2000s decades, seemingly opposite to what took place in France where the poppy drought was compensated for by lower retail prices in order to retain customers, and poor quality of street-level heroin. 46 Moreover, customs seizures and outreach field studies have drawn attention to the increasing availability and accessibility of heroin in France in recent years. 47 While heroin availability and usage was long restricted to urban areas, its use has spread within the context of a decentralized organization of heroin retail sales toward smaller metropolitan and rural areas, 48 a trend similar to that observed in the United States. 49 However, injecting drugs cannot be reduced to a mere corollary of heroin use, often smoked or sniffed nowadays. 41 Recent reports from harm reduction facilities suggested that injecting buprenorphine is a common practice among opioid substitution treatment clients, perpetuating a previously observed trend. 50 Intravenous injection is frequently mentioned by partygoers attending recreational settings and large dancing events, and has been increasingly reported as a route of administration among the most deprived stimulants users (cocaine, amphetamines, including methylphenidate (Ritaline ® ), MDMA). In other words, people who inject drugs nowadays are indicative of a more diverse, changing population that it once was, with a relative increase of female IDU. These evidences are a strong call to expand the scope of prevention policies towards an incrementally more inclusive perspective of what defines injecting drugs.
Limitations of this study
The results of this study should be interpreted with caution as a certain number of limitations arise. From a practical perspective, the participation of treatment centres is voluntary and the inclusion of a treatment centre from year to year is not automatic There is no common system for attributing identifiers to clients in use amongst treatment centres, thus making it impossible to track an individual from one structure to another. Therefore, the approach used here is based on an implicit hypothesis of exclusivity with clients seen in one centre only. In practice, the assumption holds when dealing with individuals in treatment for whom the relationship of trust established with the treatment team is crucial for following-through with rehabilitation. A likely solution to this issue would be to establish a common system of identifiers across all centres. However, this proposal has been met with great reluctance from within both the medical community and centre staff, where client anonymity is regarded as an essential pre-condition in order to reach as many users as possible. Furthermore, public authorities lack the legal framework to enforce such a measure, which may only be extended on a collaborative basis. From a methodological perspective, it should be borne in mind that the empirical hypothesis of similarity between unobserved individuals and individuals seen once cannot be tested and is likely to be violated. Moreover, heterogeneity remains a main feature in CR studies: if ignored, it leads to an estimated population size that is too low. 24 This issue is partly dealt with by focusing on clients recorded once or twice, and by the explicit inclusion of covariates in a multilevel setting. Although an improvement, covariates are no panacea since all individuals within a specific covariate group are assumed to have equal capture probabilities, an assumption that may not hold in practice. The models need to be refined and advanced to incorporate alternative information 4 . Additional factors that were unaccounted for, such as type of household, housing and housing stability, professional activity or incomes, can also influence capture probabilities, but were poorly answered and consequently discarded. Ideally, external validation should be pursued to corroborate the results. 4, 51 Unfortunately, cross-reference sources of data on this particular topic are lacking, a drawback that may potentially undermine the credibility of the estimates provided. This view emphasizes the need for further investigation in order to provide reliable and comparable estimates over time.
Finally, the choice of a novel statistical procedure is not only a matter of seeking reliable outcomes but also of balance between its benefits and flaws. Here, strength does not necessarily lie in numbers as multilevel modelling is a demanding procedure, especially when applied to tens of thousands of individuals, and convergence issues may arise. Moreover, the issue of sample size is not restricted to individual-level data: no estimates by geographical area were provided here, since multilevel modelling requires a certain number of (two-level) centres to perform adequately. In some administratively defined areas, this number of centres appeared to be too small.
Conclusion
The method appears to be a reasonable alternative to the organization of the field survey and the extrapolation of local results to provide estimates at national level. 5 Regardless of the sophistication of the modelling process however, the provided estimates are rough numbers and should be interpreted accordingly. Since no model can handle the complexity and heterogeneity of substance use patterns, the results would greatly benefit from a multisource approach and the use of various procedures to confirm previously obtained results.
